May 2021: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

May 27, 2021

Article: Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis Published in: N Engl J Med. 2021;384(18):1705-1718. https://www.nejm.org/doi/full/10.1056/NEJMoa2033400 Authors: Dorman SE, Nahid P, Kurbatova EV, et al. Summary: The Tuberculosis...

April 2021: IMPAACT 2010/VESTED trial evaluates the virological efficacy and safety of ART regimens containing DTG when started in pregnancy

Apr 29, 2021

Article: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT...

March 2021: Expanded, population-level access to PrEP through the SEARCH study, with a flexible service delivery model, associated with lower HIV incidence among PrEP initiators in rural communities in Kenya and Uganda

Mar 30, 2021

Article: HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda. Published in: PLoS Med. 2021;18(2):e1003492 https://doi.org/10.1371/journal.pmed.1003492 Authors: Koss CA,...

February 2021: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Feb 23, 2021

Article: Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study Published in: Lancet HIV. 2021;8(2):e87-e95 https://doi.org/10.1016/S2352-3018(20)30304-0 Authors: Baeten JM, Palanee-Phillips T,...

January 2021: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results

Feb 1, 2021

Article and Study Summary Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Published in: Lancet. 2020;396 (10267):1994-2005...

Journal Club